Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Brian_Finrow
|
| gptkbp:collaboratesWith |
pharmaceutical companies
US government agencies |
| gptkbp:developedBy |
antibody drugs
oral therapeutics |
| gptkbp:focusesOn |
infectious diseases
biologics gastrointestinal diseases oral antibody drugs therapeutic proteins |
| gptkbp:foundedYear |
2017
|
| gptkbp:founder |
gptkb:Jim_Roberts
gptkb:Brian_Finrow |
| gptkbp:fundedBy |
gptkb:National_Institutes_of_Health
gptkb:US_Department_of_Defense gptkb:Bill_&_Melinda_Gates_Foundation |
| gptkbp:headquartersLocation |
gptkb:Seattle,_Washington,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lumen Bioscience
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:technology |
genetically engineered spirulina
|
| gptkbp:website |
https://www.lumen.bio/
|
| gptkbp:bfsParent |
gptkb:Breakthrough_Energy_Ventures
|
| gptkbp:bfsLayer |
5
|